(19R,20S)-10,20-diethyl-7,19,20-trihydroxy-18-methylidene-17-oxa-3,13-diazapentacyclo[11.9.0.02,11.04,9.015,21]docosa-1(22),2,4(9),5,7,10,15(21)-heptaen-14-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (19R,20S)-10,20-diethyl-7,19,20-trihydroxy-18-methylidene-17-oxa-3,13-diazapentacyclo[11.9.0.02,11.04,9.015,21]docosa-1(22),2,4(9),5,7,10,15(21)-heptaen-14-one
• 化学式: C₂₄H₂₄N₂O₅
• 分子量: 420.5
• InChiKey: JZURXFKMSREYTL-UPVQGACJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  31
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  103
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• CAMPTOTHECIN COMPOUND CONTAINING STABLE 7-MEMBERED LACTONE RING, PREPARATION METHOD AND USE
  申请人：Lv Wei

  公开号：US20140128421A1

  公开（公告）日：2014-05-08

  Provided are a camptothecin compound containing 7-membered lactone ring, as shown in general formula I, and pharmaceutically acceptable salt thereof, as well as the preparation method and use thereof. In general formula I, R 1 is H, a C1˜C3 alkyl, acetyl or propionyl; R 2 is H, a C1˜C6 alkyl, a C3˜C6 cycloalkyl, piperidyl; or a C1˜C6 alkyl substituted by an amino; R 3 is H, a C1˜C3 alkyl, or a C1˜C6 alkyl substituted by an amino; R 4 is H, a hydroxyl, or a C1˜C6 alkoxy; R 5 is H, or a C1˜C6 alkoxyl; or R 4 and R 5 are linked to each other to form —OCH 2 O— or —OCH 2 CH 2 O—. The compound has good anti-tumor activity, and can be clinically used via oral administration, intravenous injection, and intramuscular injection, among others.
• US9115150B2
  申请人：——

  公开号：US9115150B2

  公开（公告）日：2015-08-25